ICICI Securities Ltd. | Retail Equity Research The USFDA has lifted the import alert from Sun's Mohali (erstwhile Ranbaxy facility) facility and removed the same from the Official Action Initiated (OAI) status. This proposed action will clear the path for Sun Pharma to supply approved products from the Mohali facility to the US market, subject to normal USFDA regulatory requirements. The USFDA had taken action against the Mohali facility in 2013 when it ordered the facility to be fully subject to Ranbaxy's consent decree of permanent injunction....